Abcam, ab151376, Recombinant Human GIP protein

Size: 10µg
Recombinant Human GIP protein is a Human Full Length protein, in the 26 to 281 aa range, expressed in Cell Culture, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, HPLC.
Key facts
Purity:>95% SDS-PAGE,
Endotoxin level:< 1 EU/µg,
Expression system:Cell Culture,
Tags:His tag C-Terminus,
Applications:SDS-PAGE, HPLCSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:Q9BXJ1,
Animal free:No,
Carrier free:No,
Species:Human,
Reconstitution:Reconstitute in PBS,
Storage buffer:pH: 7.2

Product details:
Previously labelled as CTRP1.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Glucose-dependent Insulinotropic Polypeptide (GIP) also known as gastric inhibitory polypeptide is a hormone with a molecular mass around 5 kDa. It is a 42-amino acid peptide secreted by the K cells in the duodenum and jejunum of the small intestine. This protein interacts with the GIP receptor which is found in various tissues including pancreatic beta cells adipose tissue and the central nervous system. Researchers utilize GIP ELISA for detecting and quantifying this peptide in research studies.
Biological function summary
The GIP plays a significant role in stimulating insulin secretion in response to glucose intake which does not function alone. It works as part of the enteroinsular axis influencing nutrient uptake and metabolism. GIP also regulates fat metabolism by acting on adipocytes therefore playing a part in energy homeostasis. The exploration of GIP activity often involves MSD assay development to better understand its biological implications.
Pathways
The glucose-stimulated insulin secretion pathway incorporates GIP to enhance the release of insulin from the pancreas. It interacts with other proteins such as insulin and glucagon-like peptide-1 (GLP-1) to exert its glucose-lowering effects. GIP's involvement in the incretin pathway supports the body's maintenance of energy balance and glucose homeostasis under normal physiological conditions.
Glucose homeostasis dysfunction links GIP to type 2 diabetes and obesity. Impairments in GIP secretion or receptor signaling are associated with these metabolic disorders. Studies suggest that dysregulation of GIP along with related proteins like insulin can contribute to disease progression. By targeting GIP researchers at places like Abcam are looking for potential therapies to tackle these health challenges.